CoChat

Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy

Open access

The DOI matches its Crossref record; 86 of the 88 references it cites were found in a registry or an index.

Abstract

Immune checkpoint blockade (ICB) has improved outcomes for patients with advanced cancer, but the determinants of response remain poorly understood. Here we report differential effects of mutations in the homologous recombination genes BRCA1 and BRCA2 on response to ICB in mouse and human tumors, and further show that truncating mutations in BRCA2 are associated with superior response compared to those in BRCA1. Mutations in BRCA1 and BRCA2 result in distinct mutational landscapes and differentially modulate the tumor-immune microenvironment, with gene expression programs related to both adaptive and innate immunity enriched in BRCA2-deficient tumors. Single-cell RNA sequencing further revealed distinct T cell, natural killer, macrophage, and dendritic cell populations enriched in BRCA2-deficient tumors. Taken together, our findings reveal the divergent effects of BRCA1 and BRCA2-deficiency on ICB outcome, and have significant implications for elucidating the genetic and microenvironmental determinants of response to immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s43018-020-00139-8

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 86 references

Cited by

See all 234

Metadata

Authors
Samstein, R. M., Krishna, C., Ma, X., Pei, X., Lee, K.-W., Makarov, V., Kuo, F., Chung, J., Srivastava, R. M., Purohit, T. A., Hoen, D. R., Mandal, R., Setton, J., Wu, W., Shah, R., Qeriqi, B., Chang, Q., Kendall, S., Braunstein, L., Weigelt, B., Blecua Carrillo Albornoz, P., Morris, L. G. T., Mandelker, D. L., Reis-Filho, J. S., de Stanchina, E., Powell, S. N., Chan, T. A., & Riaz, N.
Affiliations
  • Mount Sinai Hospital (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • Cleveland Clinic (US)
Corresponding author
  • Chan, Timothy A.
  • Riaz, Nadeem
Venue
Nature Cancer
Published
2020-11-16
Volume
1
Issue
12
Pages
1188-1203
ISSN
2662-1347 (ISSN-L)
OpenAlex
W3106384965
Cited by
219
References
88
Citations by year
2026: 33 · 2025: 38 · 2024: 30 · 2023: 43 · 2022: 41 · 2021: 33
FWCI
10.66
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Cancer (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Department of Health & Human Services | NIH | NIH Office of the Director (DP5-OD028171)
  • Burroughs Wellcome Fund
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54 OD020355, R35 CA232097)
  • Pershing Square Foundation
  • EIF | Stand Up To Cancer
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords
BRCA1, BRCA2, immune checkpoint blockade, immunotherapy response, tumor microenvironment, homologous recombination deficiency, truncating mutations, mutational landscape, innate and adaptive immunity, T cells, natural killer cells, macrophages, dendritic cells, single-cell RNA sequencing
MeSH terms
Immune Checkpoint Inhibitors, Animals, Humans, Immunotherapy, Mutation, Neoplasms, BRCA1 Protein, Genes, BRCA2, BRCA2 Protein, Mice, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. https://app.cochat.ai/papers/10.1038/s43018-020-00139-8
The paper
Samstein, R. M., Krishna, C., Ma, X., Pei, X., Lee, K.-W., Makarov, V., Kuo, F., Chung, J., Srivastava, R. M., Purohit, T. A., Hoen, D. R., Mandal, R., Setton, J., Wu, W., Shah, R., Qeriqi, B., Chang, Q., Kendall, S., Braunstein, L., . . . Riaz, N. (2020). Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nature Cancer. https://doi.org/10.1038/s43018-020-00139-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.